Literature DB >> 31155728

Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group.

Joanne Joseph1,2, David Rabbolini3,4, Anoop K Enjeti5, Emmanuel Favaloro6,7, Marie-Christine Kopp4, Simon McRae8, Leonardo Pasalic6,7, Chee Wee Tan8, Christopher M Ward3,4, Beng H Chong9.   

Abstract

INTRODUCTION: Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder that occurs following the administration of heparin and is caused by antibodies to platelet factor 4 and heparin. Diagnosis of HIT is essential to guide treatment strategies using non-heparin anticoagulants and to avoid unwanted and potential fatal thromboembolic complications. This consensus statement, formulated by members of the Thrombosis and Haemostasis Society of Australia and New Zealand, provides an update on HIT pathogenesis and guidance on the diagnosis and management of patients with suspected or confirmed HIT. MAIN RECOMMENDATIONS: A 4Ts score is recommended for all patients with suspected HIT prior to laboratory testing. Further laboratory testing with a screening immunoassay or confirmatory functional assay is not recommended in individuals with a low 4Ts score. However, if there are missing or unreliable clinical data, then laboratory testing should be performed. A positive functional assay result confirms the diagnosis of HIT and should be performed to confirm a positive immunoassay result. Heparin exposure must be ceased in patients with suspected or confirmed HIT and initial treatment with a non-heparin alternative instituted. Non-heparin anticoagulants (danaparoid, argatroban, fondaparinux and bivalirudin) used to treat HIT should be given in therapeutic rather than prophylactic doses. Direct oral anticoagulants may be used in place of warfarin after patients with HIT have responded to alternative parenteral anticoagulants with platelet count recovery. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: These are the first Australasian recommendations for diagnosis and management of HIT, with a focus on locally available diagnostic assays and therapeutic options. The importance of examining both clinical and laboratory data in considering a diagnosis of HIT cannot be overstated.
© 2019 AMPCo Pty Ltd.

Entities:  

Keywords:  Anticoagulants; Blood platelet disorders; Guidelines as topic

Year:  2019        PMID: 31155728     DOI: 10.5694/mja2.50213

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

Review 1.  Bayes' formula: a powerful but counterintuitive tool for medical decision-making.

Authors:  M P K Webb; D Sidebotham
Journal:  BJA Educ       Date:  2020-04-19

2.  Early Suspicion of Heparin-Induced Thrombocytopenia for Successful Free Flap Salvage: Reports of Two Cases.

Authors:  Turan Mehdizade; Osman Kelahmetoglu; Volkan Gurkan; Güven Çetin; Ethem Guneren
Journal:  J Hand Microsurg       Date:  2020-06-30

Review 3.  Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19.

Authors:  Zheng Cai; Mark I Greene; Zhiqiang Zhu; Hongtao Zhang
Journal:  Antibodies (Basel)       Date:  2020-10-10

4.  Clinical outcomes of bivalirudin versus heparin in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion.

Authors:  Xiaochun Zhang; Qinchun Jin; Dehong Kong; Cuizhen Pan; Xian Zhang; Dan Zhou; Zhiyun Shen; Daxin Zhou; Junbo Ge
Journal:  Ann Transl Med       Date:  2021-04

Review 5.  The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19.

Authors:  Emmanuel J Favaloro; Brandon Michael Henry; Giuseppe Lippi
Journal:  Int J Lab Hematol       Date:  2021-05-17       Impact factor: 3.450

Review 6.  Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS.

Authors:  Emmanuel J Favaloro; Leonardo Pasalic; Giuseppe Lippi
Journal:  Antibodies (Basel)       Date:  2022-01-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.